ATOSSA THERAPEUTICS, INC.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
ATOS$2.14+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders' Equity
(amounts in thousands, except share data)
| Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Convertible Preferred Stock · Common Stock · Additional · Treasury Stock · Accumulated · Stockholders' | ||||||||
| Shares | Amount | Shares | Amount | Paid-in Capital | Amount | Deficit | Equity | |
| Balance at December 31, 2023 | 582 | $— | 125,304,064 | $22,792 | $255,987 | $(1,475) | $(186,288) | $91,016 |
| Issuance of common stock upon warrant exercise | — | — | 203,750 | 37 | 167 | — | — | 204 |
| Stock-based compensation | — | — | — | — | 417 | — | — | 417 |
| Net loss | — | — | — | — | — | — | (5,878) | (5,878) |
| Balance at March 31, 2024 | 582 | $— | 125,507,814 | $22,829 | $256,571 | $(1,475) | $(192,166) | $85,759 |
| Issuance of common stock upon warrant exercise | — | — | 100,000 | 18 | 82 | — | — | 100 |
| Issuance of common stock upon option exercise | — | — | 268,998 | 48 | 180 | — | — | 228 |
| Shares withheld related to cashless exercise of options and taxes | — | — | (119,396) | (21) | (207) | — | — | (228) |
| Stock-based compensation | — | — | — | — | 352 | — | — | 352 |
| Net loss | — | — | — | — | — | — | (6,049) | (6,049) |
| Balance at June 30, 2024 | 582 | $— | 125,757,416 | $22,874 | $256,978 | $(1,475) | $(198,215) | $80,162 |
| Total | ||||||||
| Convertible Preferred Stock · Common Stock · Additional · Treasury Stock · Accumulated · Stockholders' | ||||||||
| Shares | Amount | Shares | Amount | Paid-in Capital | Amount | Deficit | Equity | |
| Balance at December 31, 2024 | 582 | $— | 129,170,004 | $23,488 | $261,256 | $(1,475) | $(211,792) | $71,477 |
| Stock-based compensation | — | — | — | — | 563 | — | — | 563 |
| Net loss | — | — | — | — | — | — | (6,718) | (6,718) |
| Balance at March 31, 2025 | 582 | $— | 129,170,004 | $23,488 | $261,819 | $(1,475) | $(218,510) | $65,322 |
| Issuance of common stock upon Series B preferred stock conversion | (5) | — | 1,420 | — | — | — | — | — |
| Stock-based compensation | — | — | — | — | 796 | — | — | 796 |
| Net loss | — | — | — | — | — | — | (8,423) | (8,423) |
| Balance at June 30, 2025 | 577 | $— | 129,171,424 | $23,488 | $262,615 | $(1,475) | $(226,933) | $57,695 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.